Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes.

Autor: Griffiths K; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland., Maxwell AP; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland., McCarter RV; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland., Nicol P; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland., Hogg RE; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland., Harbinson M; Centre for Medical Education, Queen's University Belfast, Belfast, Northern Ireland.; Department of Cardiology, Belfast Health and Social Care Trust, Royal Hospital, Belfast, Northern Ireland., McKay GJ; Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland. g.j.mckay@qub.ac.uk.; Centre for Public Health, Institute of Clinical Sciences, Block B, Royal Victoria Hospital, Queen's University Belfast, Belfast, BT12 6BA, Ireland. g.j.mckay@qub.ac.uk.
Jazyk: angličtina
Zdroj: Irish journal of medical science [Ir J Med Sci] 2019 Nov; Vol. 188 (4), pp. 1175-1183. Date of Electronic Publication: 2019 Mar 09.
DOI: 10.1007/s11845-019-01996-8
Abstrakt: Background: Serum amyloid A (SAA) is secreted by liver hepatocytes in response to increased inflammation whereupon it associates with high-density lipoprotein (HDL) and alters the protein and lipid composition of HDL negating some of its anti-atherogenic properties.
Aims: To identify variants within the SAA gene that may be associated with SAA levels and/or cardiovascular disease (CVD).
Methods: We identified exonic variants within the SAA genes by deoxyribonucleic acid (DNA) Sanger sequencing. We tested the association between SAA variants and serum SAA levels in 246 individuals with and without CVD.
Results: Increased SAA was associated with rs2468844 (beta [β] = 1.73; confidence intervals [CI], 1.14-1.75; p = 0.01), rs1136747 (β = 1.53 (CI, 1.11-1.73); p = 0.01) and rs149926073 (β = 3.37 (CI, 1.70-4.00); p = 0.02), while rs1136745 was significantly associated with decreased SAA levels (β = 0.70 (CI, 0.53-0.94); p = 0.02). Homozygous individuals with the SAA1.3 haplotype had significantly lower levels of SAA compared with those with SAA1.1 or SAA1.5 (β = 0.43 (CI, 0.22-0.85); p = 0.02) while SAA1.3/1.5 heterozygotes had significantly higher SAA levels compared with those homozygous for SAA1.1 (β = 2.58 (CI, 1.19-5.57); p = 0.02).
Conclusions: We have identified novel genetic variants in the SAA genes associated with SAA levels, a biomarker of inflammation and chronic disease. The utility of SAA as a biomarker for inflammation and chronic disease may be influenced by underlying genetic variation in baseline levels.
Databáze: MEDLINE
Externí odkaz: